美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

HORIZON KINETICS MEDICAL ETF

35.29

+0.33190.95%

盤後：35.300.0109+0.03%16:10 EDT

成交量：227

成交額：8,052

市值：1,658.40萬

市盈率：- -

高：35.30

開：35.30

低：35.29

收：34.96

52周最高：37.90

52周最低：28.87

股本：46.99萬

流通股本：46.99萬

量比：0.09

換手率：0.05%

股息：0.41

股息率：1.16%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

禮來完成對Ataibeckley收購，加速推進難治性抑鬱症及其他精神健康疾病療法研發

創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用

重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線

放量普跌！有色突遭重挫，創新藥跌跌不休！光模塊逆市獨漲，高「光」創業板人工智能ETF（159363）V型拉升

貝泰妮：注射用透明質酸鈉溶液獲得醫療器械註冊證

東方生物：獲得多項境外醫療器械註冊證

九強生物：取得I型膠原氨基端延長肽測定試劑盒醫療器械註冊證

麥科田赴港上市：併購拼出的醫療器械版圖，暗藏多重隱憂

昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數

一品紅痛風創新藥Ⅲ期臨床達到主要終點大中華區銷售峯值預計達19.5億元

無AI增長：八大精選股票

港股異動 | 創新藥概念股持續調整海外利率預期反覆 2026國談收官進入結果等待期

百龍創園在昆明成立生物科技公司

港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序

【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善

深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行

涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/MEDX/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2891,"timestamp":1789416000000,"preClose":34.9572,"halted":0,"volume":227,"hourTrading":{"tag":"盘后","latestPrice":35.3,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0.0109,"changeRate":0.000309,"amplitude":0},"delay":0,"changeRate":0.009494467520281871,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"已收盤","change":0.3319,"latestTime":"09-14 16:00:00 EDT","open":35.3,"high":35.3,"low":35.2891,"amount":8052,"amplitude":0.000312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.9572,"sharesOutstanding":569946,"nav":34.94,"aum":16419913.24,"dividendRate":0.01159,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.3,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0.0109,"changeRate":0.000309,"amplitude":0},"volumeRatio":0.087916},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.087916,"shares":469946,"dividePrice":0.409,"high":35.3,"amplitude":0.000312,"preClose":34.9572,"low":35.2891,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2891,"eps":0,"divideRate":0.01159,"volume":227,"delay":0,"ttmEps":0,"open":35.3,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":36.6906,"twentyDayClose":35.6938,"sixtyDayClose":34.2263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1154710349","title":"禮來完成對Ataibeckley收購，加速推進難治性抑鬱症及其他精神健康疾病療法研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1154710349","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154710349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 21:04","pubTimestamp":1789131857,"startTime":"0","endTime":"0","summary":"礼来公司已正式完成对Ataibeckley的收购事宜。这一战略举措，旨在为那些饱受难治性抑郁症以及其他精神健康疾病困扰的患者，开辟全新的治疗路径。此项交易的落定，标志着礼来在精神健康领域的布局迈出了坚实一步。礼来此番动作，显然意在突破这一瓶颈。通过将Ataibeckley的研发资产与专业团队纳入麾下，礼来有望整合各方资源，加速相关候选药物的研发进程。礼来此举，无疑将为其在精神科药物市场的未来竞争增添重要砝码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRUH","LU1917777945.USD","LU1232071149.USD","IE00BWXC8680.SGD","LU0097036916.USD","IE0002141913.USD","FHLC","LU1623119135.USD","LU2023251221.USD","IE00BJJMRX11.SGD","LU2108987350.USD","LU2552382132.HKD","LU0820562030.AUD","IE00B7KXQ091.USD","BK4585","LU2361044865.SGD","SG9999014880.SGD","LU0094547139.USD","LU0471298694.HKD","LU2237443895.HKD","LU1548497426.USD","BK4534","LU2168563687.JPY","IXJ","LU2552382215.SGD","LU0689472784.USD","SG9999017495.SGD","SG9999014914.USD","IE0009355771.USD","SGXZ81514606.USD","LU0210536198.USD","LU0238689110.USD","LU1093756325.SGD","LU2471134523.USD","PPH","LU1366192091.USD","IE0004445015.USD","SGXZ57979304.SGD","LU1814569148.SGD","LU2063271972.USD","LU1983299246.USD","GB00BDT5M118.USD","LU2168564065.EUR","LU0683600562.USD","LU0889565916.HKD","LU2602419157.SGD","LU0133085943.USD","LU2089283258.USD","LU0198837287.USD","LU2089984988.USD","LU2552382058.USD","GDOC","LU0158827948.USD","LU0256863902.USD","SG9999014906.USD","LU0354030438.USD","LU0385154629.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0256863811.USD","LU0964807845.USD","LU1720051017.SGD","LU0289739699.SGD","LU2211815571.USD","LU2324357040.USD","LU2361044949.HKD","IE00BJJMRZ35.SGD","LU1551013425.SGD","LU2468319806.SGD","LU0320765059.SGD","LU0466842654.USD","IE00B2B36J28.USD","LU2750360641.GBP","LU0823434583.USD","SG9999018865.SGD","LU0345770308.USD","LU2756315664.SGD","IE00B1BXHZ80.USD","LU1868837300.USD","LU0203202063.USD","LU2237443622.USD","LU0354030511.USD","CANC","IE00B1XK9C88.USD","LU2089284900.SGD","LU2491050154.USD","FTXH","LU0266013472.USD","IE0001KFT4U8.USD","LU2750360997.AUD","IE00BFSS8Q28.SGD","LU0109391861.USD","SG9999014898.SGD","LU1868836591.USD","LU2361045086.USD","LU2168564495.EUR","LU0417517546.SGD","IE0005OL40V9.USD","LU0823434740.USD","LU2112291526.USD","IE0004445239.USD","LU2756315318.SGD","LU0786609619.USD","IE00BFSS7M15.SGD","LU0471298777.SGD","LU2360106947.USD","LU0096364046.USD","LU1720051108.HKD","LU2023250504.SGD","WDNA","LU0109394709.USD","LU2265009873.SGD","LU2237443465.HKD","IE00B4R5TH58.HKD","SGXZ99366536.SGD","SG9999013999.USD","SG9999015945.SGD","LU2236285917.USD","LU2106854487.HKD","IYH","IE00BN29S564.USD","MHIP","LU0316494557.USD","SG9999001176.USD","LU2491050071.SGD","SGXZ51526630.SGD","LU1280957306.USD","LU0122379950.USD","LU1057294990.SGD","LU2417539215.USD","LU2456880835.USD","LU1629891620.HKD","LU1069344957.HKD","LLY","LU0345770993.USD","THNR","LU0708995401.HKD","LU2237443978.SGD","LU2023250330.USD","IE00BJJMRY28.SGD","LU2271345857.HKD","CURE","MEDX","LU0882574139.USD","LU2746668461.USD","LU0174119429.USD","LU0323591593.USD","LU0640476718.USD","SG9999018857.SGD","LU0672654240.SGD","LU2237438978.USD","LU0114720955.EUR","LU1064131342.USD","LU2357305700.SGD","SG9999015952.SGD","LU0882574055.USD","LU1691799644.USD","IE00BJT1NW94.SGD","LU2028103732.USD","LU2168564222.USD","TMED","BK4588","SGXZ31699556.SGD","LU0106261372.USD","RXL","IE00BK4W5L77.USD","LU1267930730.SGD","LU2462157665.USD","IE00B775H168.HKD","LU0061475181.USD","XLV","IE00BK4W5M84.HKD","LU0820561818.USD","LU0320765992.SGD","HRTS","ILDR","LU1988902786.USD","LU0820561909.HKD","AGNG","LU2087625088.SGD","LU2746668974.SGD","SG9999001176.SGD","MEDI","LU2471134879.HKD","BK4516","LU0432979614.USD","BK4533","LLYX","LU1035775433.USD","LU2491049909.HKD","LU2237443549.SGD","LU0787776722.HKD","LU0943347566.SGD","LU0353189763.USD","LU2471134952.CNY","LU2111349929.HKD","LU1127390331.HKD","IE00BJLML261.HKD","BK4007","LU1323610961.USD","LU2462591350.SGD","LU1979441026.SGD","LU1974910355.USD","IE00BKDWB100.SGD","LU1989771016.USD","LU0225283273.USD","LLII","SG9999015986.USD","LU2461242641.AUD","LU0158827781.USD","LU1868837136.USD","LU1804176565.USD","LLYZ","JDOC","LU0234572021.USD","LU0456855351.SGD","LU0203201768.USD","LU1061106388.HKD","LU1093756168.USD","VHT","LU0079474960.USD","ELIS","OZEM","LU0006306889.USD","IE00BKPKM429.USD","SG9999015978.USD","LU1023059063.AUD","IHE","PJP","LU0823416689.USD","LU2213496289.HKD","LU2264538146.SGD","ELIL","LU1868836914.USD","BK4599","LU1145028129.USD","LU0353189680.USD","LU2896262040.SGD","BK4581","LU1868836757.USD","LU2237443382.USD","LU2168564149.EUR","LU1712237335.SGD","LU2471134796.USD","IE00B4JS1V06.HKD","LU1291159041.SGD","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666798529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","BK1574","ORR","159992","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529140","title":"重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529140","media":"新浪基金","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529140?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:17","pubTimestamp":1789125420,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhry5675751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","MEDX","520880","FLHK","BK1574","159992","BK1161","06978","IBBQ","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666452917","title":"放量普跌！有色突遭重挫，創新藥跌跌不休！光模塊逆市獨漲，高「光」創業板人工智能ETF（159363）V型拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666452917","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666452917?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:15","pubTimestamp":1789125300,"startTime":"0","endTime":"0","summary":"有色板块领跌全市场，揽尽有色金属行业龙头的有色ETF华宝标的指数收跌4.04%失守所有均线。FCC政策落地，光通信担忧明显缓解，光模块龙头逆市走强，中际旭创逆市收涨4%，新易盛涨近3%，高“光”创业板人工智能ETF华宝标的指数日内“V”型拉升。中际旭创、新易盛逆市上涨，高“光”指数V型拉升！*布局高“光”主线+AI应用，建议关注创业板人工智能ETF华宝及场外联接，重点布局光模块CPO龙头，兼顾AI应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrq6694331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AGIX","LCLG","VUSE","159363","ARTY","QID","PBOT","AAOZ","000001.SH","CNXT","GK","IBBQ","399006","NBDS","CHAT","KOMP","159915","159982","LYTE","515890","06978","AIFD","QQA","159992","LUMA","WPAI","MVPS","AQGX","DQJN","MFIG","399300","FDN","MEDX","QSWN","CPNQ","510300","161631","NEWZ","TARK","TECY","QTOC","159876","512510","AIBU","LNGR","FWD","CWC","AIQU","OGIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666525651","title":"貝泰妮：注射用透明質酸鈉溶液獲得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666525651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666525651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:17","pubTimestamp":1789121838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDEV","LNGR","AGNG","GDOC","LGHT","PTH","RSPH","HART","IEIH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666230575","title":"東方生物：獲得多項境外醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666230575","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666230575?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:05","pubTimestamp":1789121126,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDEV","LNGR","AGNG","GDOC","LGHT","PTH","RSPH","HART","IEIH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544799","title":"九強生物：取得I型膠原氨基端延長肽測定試劑盒醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544799?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:50","pubTimestamp":1789113020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","MDEV","LNGR","RSPH","LGHT","HART","PTH","MEDX","IEIH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938544","title":"麥科田赴港上市：併購拼出的醫療器械版圖，暗藏多重隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938544","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666938544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"近日，麦科田正式开启港股全球发售。盈利脆弱性在 2026 年一季度进一步暴露，上市前夕再度出现 252.7 万元亏损。靠并购快速拼出业务版图的麦科田，即将站上港股资本市场。对于麦科田而言，如何完成并购资产的深度整合、夯实自主研发实力、化解商誉与渠道危机，将决定它能否从并购拼凑的企业，蜕变为具备内生竞争力的医疗器械公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5385233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","XMMO","LNGR","02041","MYLD","RSPH","MEDX","LGHT","BK1574","159883","KCE","PTH","09996","BK4585","AGNG","IEIH","BK1583","GDOC","CALF","BK4588","HART","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544925","title":"昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544925","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544925?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"9 月 6 日，昂利康发布公告宣布终止与亚飞生物、亲合力的 IMD\u001e1005肿瘤抗体药物授权许可合作。02主业盈利出现下滑，创新转型面临双重考验创新药引进受挫的同时，昂利康主业经营已经显现压力。原料药业务是昂利康的基本盘，业绩下滑说明核心主业易受行业周期、市场供需波动冲击，自身抗周期能力有待加强。未来昂利康既要稳固原料药基本盘，也需要平衡好资金投入与管线风险，审慎推进授权引进类项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5384750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","IBBQ","BK0239","LNGR","MEDX","002940","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544603","title":"一品紅痛風創新藥Ⅲ期臨床達到主要終點 大中華區銷售峯值預計達19.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544603","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544603?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:34","pubTimestamp":1789112040,"startTime":"0","endTime":"0","summary":"近日，一品红自愿披露关于痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点的公告。商业化权益方面，AR882为一品红自主研发的1类创新药，在大中华区拥有完整的开发、生产与商业化权益，且一品红具备成熟的自有慢病药商业化团队，无需对外支付销售分成。结合0.70的临床成功概率，最终AR882大中华区痛风适应症管线的风险调整净现值约为5.5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-11/doc-inirmvzz2155509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1574","IBBQ","MEDX","300723","06978","BK0239","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114311100","title":"無AI增長：八大精選股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1114311100","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114311100?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 13:06","pubTimestamp":1789103219,"startTime":"0","endTime":"0","summary":"人工智能究竟是一场第四次工业革命，还是一个超级泡沫？答案取决于你听的是华尔街哪位预言家的高论。它或将开启一个超级生产力周期，或将引发崩盘——亦或是两者兼而有之。它将攻克疾病与贫困，除非它先降低了大规模毁灭的门槛。有时实在令人疲惫不堪。以下八只颇具前景的股票，幸运地与AI关联甚微。没有事件视界，我们有的是一场盛大的电子游戏发布。我们不敢保证这份名单100%与AI绝缘。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU0158827781.USD","MHIP","IE00BJLML261.HKD","IXJ","LU2264538146.SGD","SG9999014906.USD","IE00BWXC8680.SGD","LU0471298694.HKD","LU0130102774.USD","LU2237438978.USD","LU0385154629.USD","LU2461242641.AUD","LU2168564149.EUR","LU0321505439.SGD","LU0320765059.SGD","SGXZ31699556.SGD","LU0006306889.USD","LU2746668461.USD","LU0225771236.USD","LU2108987350.USD","LU1917777945.USD","LU0321505868.SGD","LU0353189680.USD","LU0079474960.USD","LU1057294990.SGD","LU0106831901.USD","BK4142","LU2168564495.EUR","IE00B7KXQ091.USD","BK4517","LU1074936037.SGD","LU2756315664.SGD","RCL","SG9999014898.SGD","SG9999001176.SGD","LU2417539215.USD","LU0225284248.USD","LU1551013425.SGD","LU0130517989.USD","RXL","LU0345774391.USD","LU2087625088.SGD","LU0471298777.SGD","LU0238689110.USD","LU0323591593.USD","LU1861220207.SGD","LU2028103732.USD","WDNA","IE00BJJMRY28.SGD","LU0114720955.EUR","LLII","LU2750360641.GBP","LU1868836757.USD","LU0048573561.USD","LU2211815571.USD","LU0096364046.USD","SG9999018857.SGD","LU0683600562.USD","LU1363072403.SGD","LU2462157665.USD","LU2360106947.USD","LU0477156953.USD","LU2746668974.SGD","BK4581","LU2471134523.USD","LU0251131958.USD","BK4127","LU1291159041.SGD","LU2063271972.USD","FTXH","IE00B4R5TH58.HKD","LU2357305700.SGD","BK4200","LU1668664300.SGD","IE00B2B36J28.USD","LU1988902786.USD","LU2471134796.USD","LU0251142724.SGD","LU1069347547.HKD","IE00B775H168.HKD","SCHW","LU1280957306.USD","LU0985481810.HKD","LU0203202063.USD","LU0061475181.USD","LU1868836591.USD","LU0306807586.USD","SG9999014880.SGD","IE0002141913.USD","LU1551013342.USD","TRUH","SG9999013999.USD","LU1989771016.USD","LU0266013472.USD","CANC","ILDR","OZEM","LU2462591350.SGD","LU1983299246.USD","AGNG","SGXZ57979304.SGD","LU0109391861.USD","LU2023250330.USD","VHT","IE00BN29S564.USD","LU0345770993.USD","BK4597","LU2471134952.CNY","LU2324357040.USD","IE00BKPKM429.USD","LU1064131342.USD","BK4533","LU2471134879.HKD","LU1267930730.SGD","LU2168563687.JPY","LU1868837136.USD","LU1023059063.AUD","BK4588","LU2237443549.SGD","BK4534","BK4161","LU2023250504.SGD","SG9999015945.SGD","IE0004445239.USD","LU1061106388.HKD","LU0133085943.USD","BK4589","LU2750360997.AUD","LU2552382058.USD","LU2361045086.USD","FIVE","SG9999014013.SGD","IE00BJJMRX11.SGD","LU1323610961.USD","IE00B4JS1V06.HKD","SG9999014021.USD","LU1868836914.USD","LU2213496289.HKD","GDOC","LU1127390331.HKD","LU0306806265.USD","LU0456855351.SGD","LU1153585028.USD","LU1720051108.HKD","SG9999015952.SGD","LU2552382132.HKD","ELIL","SG9999018865.SGD","LU1712237335.SGD","LU2896262040.SGD","LU0310800379.SGD","LU0210536198.USD","LU2089984988.USD","LU0122379950.USD","LU0203201768.USD","BK4516","LLYZ","BK4599","LU0158827948.USD","LU0058720904.USD","LU0225283273.USD","HRTS","LU1069344957.HKD","IE00BFSS8Q28.SGD","SG9999014005.SGD","LU0943347566.SGD","BK4585","IE0001KFT4U8.USD","MEDI","LU1720051017.SGD","IE00B19Z3581.USD","LU0640476718.USD","JDOC","LU2456880835.USD","LU0432979614.USD","SG9999014914.USD","CURE","LU1093756168.USD","ELIS","LU0256863902.USD","SG9999001176.USD","LU0354030438.USD","LU1232071149.USD","IHE","SG9999015986.USD","LU0234572021.USD","PJP","LU0971096721.USD","IE00B1XK9C88.USD","LU0109394709.USD","LU2112291526.USD","LU2602419157.SGD","LU0353189763.USD","BK4504","BK4007","IAI","LU0708995401.HKD","LU1629891620.HKD","LU1861217088.USD","LU0097036916.USD","LU2236285917.USD","LU0316494557.USD","LU0106261372.USD","SG9999001077.SGD","LU2237443978.SGD","LU0889565916.HKD","LU1670627923.USD","SGXZ99366536.SGD","IE00BK4W5L77.USD","LU0820562030.AUD","LU1093756325.SGD","IE00BFTCPJ56.SGD","SGXZ51526630.SGD","LU2360107671.USD","LU2168564065.EUR","LU0882574055.USD","LU0820561818.USD","LU2491050071.SGD","XLV","LU0823416689.USD","LU1791807156.HKD","LU0787776722.HKD","LU2111349929.HKD","LU0345770308.USD","LU1201861249.SGD","LU1814569148.SGD","SWK","LU1974910355.USD","IE00BK4W5M84.HKD","TMED","WNDR","FHLC","LU0417517546.SGD","IYH","LU0823434583.USD","LU1035775433.USD","LU2168564222.USD","LU1548497426.USD","IE00B1BXHZ80.USD","LU0823434740.USD","LU2552382215.SGD","LU0354030511.USD","LU0820561909.HKD","LU0964807845.USD","LU1868837300.USD","LU2237443895.HKD","IE00B7SZLL34.SGD","LU1691799644.USD","IE0002270589.USD","LU1035773651.USD","BK4139","LU0198837287.USD","LLY","LU1979441026.SGD","LU0320765992.SGD","IE0009355771.USD","MEDX","IE00BJT1NW94.SGD","IE00BFSS7M15.SGD","LU0708994859.HKD","LU2361044865.SGD","LU1623119135.USD","LU2237443622.USD","GB00BDT5M118.USD","LU2491050154.USD","LU0672654240.SGD","SG9999017495.SGD","IE0004445015.USD","LU0980610538.SGD","LU0882574139.USD","LU2089284900.SGD","IE00B19Z3B42.SGD","LU0786609619.USD","LU1366192091.USD","SG9999015978.USD","IE000M9KFDE8.USD","LU1670628061.USD","LU0289739699.SGD","LU2491049909.HKD","IE0005OL40V9.USD","BMRN","LU2089283258.USD","LU0689472784.USD","LU2756315318.SGD","PPH","LU2361044949.HKD","LU0256863811.USD","LU2271345857.HKD","LU0128525929.USD","SG9999014039.USD","BK4566","THNR","LU0029864427.USD","LU0466842654.USD","LU0094547139.USD","LU2468319806.SGD","SGXZ81514606.USD","LU0648001328.SGD","LU2237443465.HKD","LU1145028129.USD","LU1267930573.SGD","LU2023251221.USD","LU2265009873.SGD","IE00BKDWB100.SGD","LU0174119429.USD","IE00BJJMRZ35.SGD","LU0345774631.USD","LLYX","LU0742534661.SGD","LU2237443382.USD","LU0011850046.USD","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股異動 | 創新藥概念股持續調整 海外利率預期反覆 2026國談收官進入結果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510786?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1813983027.USD","BK4585","LNGR","LU0326950275.SGD","LU2097828805.USD","LU2097828557.USD","LU0501845795.SGD","BK1191","LU1226287875.USD","MCRO","LU1188198961.HKD","LU0067412154.USD","KURE","IBBQ","LU0455707207.USD","01801","LU1328277881.USD","BK1515","LU0149534421.HKD","LU0244354667.USD","LU1226287792.SGD","WRTH","LU0072913022.USD","02157","LU2242644610.SGD","LU2097828474.EUR","06978","LU1807302812.USD","IE0008369823.USD","09995","159992","MEDX","LU2488822045.USD","LU1831875114.USD","IE0008368742.USD","01093","KCAI","LU1960683339.HKD","BK1589","LU0880133367.SGD","LU1008478684.HKD","VXUS","IE00BZ08YS42.EUR","LU2328871848.SGD","PEVC","LU1226288170.HKD","LU1969619763.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510878","title":"百龍創園在昆明成立生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510878?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:32","pubTimestamp":1789093959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","IBBJ","BK4588","SYNB","IEIH","LNGR","MEDX","BK4585","BK4581","AGNG","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517543","title":"港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517543","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517543?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:49","pubTimestamp":1789091380,"startTime":"0","endTime":"0","summary":"消息面上，先健科技发布公告，于2026年9月9日，本公司收到国家药品监督管理局的正式书面通知，确认由本公司附属公司深圳市健心医疗科技有限公司与国家心血管病中心中国医学科学院阜外医院联合研发的LantvalTM主动脉瓣膜置换系统进入国家药品监督管理局创新医疗器械特别审查程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","KCAI","BK4585","AGNG","HART","GDOC","BK1574","09996","BK1583","01302","LGHT","PTH","LNGR","BK1600","BK1100","159883","IEIH","BK4588","MDEV","VXUS","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666127155","title":"【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2666127155","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666127155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。该机构认为，随着集采影响逐步出清叠加创新驱动和海外业务加速的双重助力，医疗器械板块业绩有望逐步改善。尽管季度业绩增速可能有所波动，Q3能否相比Q2加速尚不确定，但大趋势来看，26和27年年度业绩持续改善的确定性较强。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01302","00241","BK1247","BK1502","601066","BK1161","BK1584","BK1610","LU0173614495.USD","BK1501","BK1585","BK1100","BK1571","BK1589","BK1615","BK1600","LNGR","LU0287142896.SGD","BK1593","02235","BK1591","RSPH","MEDX","HK0000165453.HKD","LGHT","BK1574","BK1587","BK1617","02252","159883","KCE","BK1515","00853","01066","BK1189","PTH","BK0276","BK1142","HART","09996","BK1222","IEIH","AGNG","BK1583","GDOC","02190","06826","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983512","title":"深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983512","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:10","pubTimestamp":1789089045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LGHT","PTH","RSPH","BK1583","BK1507","BK1185","LU0067412154.USD","BK1582","GDOC","HART","MDEV","MEDX","IEIH","00152","BK1100","LU1152091754.HKD","159883","LU1008478684.HKD","09996","LNGR","BK1574","SG9999003461.SGD","LU0880133367.SGD","AGNG","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751737","title":"涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751737","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751737?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:17","pubTimestamp":1789085820,"startTime":"0","endTime":"0","summary":"停牌前，拨康视云报1.19港元，较2025年7月上市发行价10.1港元，累计蒸发约88%。这是一间成立于2015年、专注眼科创新药的临床阶段生物科技公司，四次递表才闯关成功，上市首日即告破发，如今在监管介入调查中股票停牌，前路未卜。证监会表示，调查仍在进行中，暂不作进一步评论。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-09-11/doc-inirmfea2271775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","REDS","BK1574","159992","KCE","LNGR","MEDX","FRHC","IPOS","BK4127","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511370?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","IBBQ","BK1161","MEDX","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519089","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519089?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:15","pubTimestamp":1789082138,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519701","title":"第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519701","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081313,"startTime":"0","endTime":"0","summary":"丨2026年9月11日星期五丨NO.1爱康医疗宣布提高股东股息分派占归母净利比例9月10日，爱康医疗基于对集团未来业绩及长期发展前景的信心，宣布股东股息分派及回报计划，截至2026年12月31日止财政年度，年度股息派付比例提高至不低于归母净利润的55%；截至2027年12月31日及2028年12月31日止财政年度各年，派息比例提升至不低于归母净利润的60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113871018788.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113871018788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","PPH","09939","IE0009355771.USD","MEDX","BK4588","BK1515","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4578","IE00BJT1NW94.SGD","NVS","LU0208291251.USD","BK4585","BK4532","IE0002141913.USD","BK4007","LU0211331839.USD","LU0070302665.USD","BK1161","159938","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":4,"totalSize":242,"code":"91000000","status":"200"}]}}